Hiromasa Takei

Shall we score? The SHALL-WE score for optimizing sclerotherapy in superficial lymphatic malformations

No standardized tool guides the decision of when to escalate beyond sclerotherapy in lymphatic malformations (LMs). We developed the SHALL-WE score (Severity, Histology, And Location—Lymphatic malformation: When to Escalate) to define the optimal sclerotherapy threshold in superf...